잠시만 기다려 주세요. 로딩중입니다.

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2

Journal of Microbiology and Biotechnology 2020년 30권 12호 p.1843 ~ 1853
구근본, 신혜진, 김해수, 김범태, 김성준, 김천생,
소속 상세정보
구근본 ( Ku Keun-Bon ) - Korea Research Institute of Chemical Technology Center for Convergent Research of Emerging Virus Infection
신혜진 ( Shin Hye-Jin ) - Korea Research Institute of Chemical Technology Center for Convergent Research of Emerging Virus Infection
김해수 ( Kim Hae-Soo ) - Korea Research Institute of Chemical Technology Center for Convergent Research of Emerging Virus Infection
김범태 ( Kim Bum-Tae ) - Korea Research Institute of Chemical Technology Center for Convergent Research of Emerging Virus Infection
김성준 ( Kim Seong-Jun ) - Korea Research Institute of Chemical Technology Center for Convergent Research of Emerging Virus Infection
김천생 ( Kim Chon-Saeng ) - Korea Research Institute of Chemical Technology Center for Convergent Research of Emerging Virus Infection

Abstract


COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.

키워드

SARS-CoV-2; COVID-19; FDA-approved drugs; repurposing screens

원문 및 링크아웃 정보

등재저널 정보